Announcement • Jun 11
Attendo AB Announces Relocation of Vårdbo Nursing Home Operations in Vallentuna Attendo AB announced that Vårdbo nursing home will relocate from its current premises at Ekebyvägen 40 to new facilities at Stendösvägen 3 in central Vallentuna. Attendo AB stated that the nursing home will remain in the same local area, helping to ensure continuity and a sense of security for residents, their families and employees. Attendo AB mentioned that the new premises will comprise approximately 3,500 square metres and accommodate 52 resident rooms. Attendo AB reported that the property will be refurbished and adapted to meet the specific needs of the operations prior to the relocation. Attendo AB indicated that the refurbishment is planned to begin in November 2026, with residents expected to move into the new premises in December 2027. Recent Insider Transactions • Jun 04
Independent Director recently sold €4.6m worth of stock On the 29th of May, Antti Ylikorkala sold around 423k shares on-market at roughly €10.99 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €4.1m more than they bought in the last 12 months. Announcement • Mar 26
Attendo AB (Publ) Announces Decline of Suvi-Anne Siimes and Tobias Lönnevall for Re-Election from the Nomination Committee Attendo AB (publ) announced Suvi-Anne Siimes and Tobias Lönnevall declined re-election for the Nomination Committee. Announcement • Feb 24
An undisclosed buyer acquired an unknown minority stake in Attendo AB (publ) (OM:ATT) from Nordstjernan AB. An undisclosed buyer acquired an unknown minority stake in Attendo AB (publ) (OM:ATT) from Nordstjernan AB on February 23, 2026. Nordstjernan AB sold its remaining shares in Attendo AB (publ).
An undisclosed buyer completed the acquisition of an unknown minority stake in Attendo AB (publ) (OM:ATT) from Nordstjernan AB on February 23, 2026. Announcement • Jun 25
Attendo AB (publ) (OM:ATT) agreed to acquire Framja Ab. Attendo AB (publ) (OM:ATT) agreed to acquire Framja Ab on June 25, 2025. The deal does not include Främja’s Norwegian operations and is expected to be completed in the third quarter of 2025. Announcement • May 08
Attendo AB Elects Hugo Lewné as Board Member Attendo AB held its Annual General Meeting on May 7, 2025. The meeting elected Hugo Lewné as the Board member. Announcement • Apr 28
Attendo AB (publ) to Report Q1, 2025 Results on May 07, 2025 Attendo AB (publ) announced that they will report Q1, 2025 results at 8:00 AM, Central European Standard Time on May 07, 2025 Announcement • Jan 13
Attendo AB (Publ) Appoints Malin Fredgardh Huber as Business Area Director Attendo AB (publ) appointed Malin Fredgardh Huber as new Business Area Director for Attendo Scandinavia. Malin brings 20 years of experience from senior positions at Attendo, the last years as Segment Director for Attendo's elderly care operations in Sweden and Denmark. Malin succeeds Patrik Högberg, who is leaving the company. She assumes responsibility and joins Attendo's executive management team. Patrik Högberg, who has led the Scandinavian operations for the past year, is leaving his role after completing an important period of integration between Attendo and Team Olivia. Malin Fredgardh Huber, born in 1975, is a registered nurse with additional education in human resources and labor relations, equivalent to a bachelor's degree in the PA program. She has participated in the Novare Women Executive Program (2015-2016) and is set to complete the leadership program "Det storartade ledarskapet" at Ledarstudion in January this year. Announcement • Dec 20
Attendo Appoints Carl Granström as General Counsel and A Member of the Executive Management Team Attendo has appointed Carl Granström as General Counsel and a member of the executive management team. He joins Attendo from Telia, where he has held several senior roles, most recently as Vice President Legal. Carl will assume his position no later than mid-March 2025, succeeding the current General Counsel and Sustainability Director, Jo-Anna Nordström, who has previously announced her departure from Attendo. Carl has over 20 years of experience as a business lawyer, both at law firms and as an in-house legal counsel, specializing in corporate governance, M&A, and commercial law. At Telia, he has held key roles across several business areas and has also worked internationally, focusing on corporate governance and acquisitions. Carl Granström holds a law degree from Stockholm University and previously worked as a lawyer at law firm Cederquist. At Telia, he has also served on several boards, both in Sweden and internationally. Carl will officially assume his new role no later than mid-March 2025. Announcement • Dec 13
Attendo AB (Publ Announces That the Director of Business and Quality Development Eric Wåhlgren to Leave Attendo and His Position in the Group Management Team Attendo's Director of Business and Quality Development, Eric Wåhlgren, has announced that he will be leaving Attendo for a role outside the company after five years in the group management team. The recruitment process to find his successor will begin immediately. Eric Wåhlgren will leave Attendo latest in June 2025 and will remain in his role during the transition period. Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: kr1.50 (vs kr1.43 in 3Q 2023) Third quarter 2024 results: EPS: kr1.50 (up from kr1.43 in 3Q 2023). Revenue: kr4.88b (up 8.8% from 3Q 2023). Net income: kr235.0m (up 2.2% from 3Q 2023). Profit margin: 4.8% (down from 5.1% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Oct 17
Attendo AB (Publ) Announces Jo-Anna Nordström Leaves as General Counsel and Sustainability Director, Effective April 2025 After more than five years as General Counsel and later also Director of Sustainability at Attendo, Jo-Anna Nordström has announced that she is moving on to a new role outside the company. Jo-Anna will leave Attendo latest in April 2025 and will remain in her role during the transition period. The recruitment process to find a successor will start immediately. Announcement • Oct 16
Attendo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025 Attendo AB (publ) announced that they will report Q4, 2024 results on Feb 06, 2025 Announcement • Oct 04
Attendo AB (publ) Appoints Josefine Uppling as Director of Communications Josefine Uppling has been appointed Communications Director for Attendo AB (publ), with responsibility for the Group's communications and public affairs. She will be a member of the Executive Management Team and will take up her position in April 2025 at the latest. Josefine Uppling has a solid background in communications, with several senior positions from major listed companies. She most recently held the position of Head of Communications and Sustainability in the Ratos Group, and has previously been Head of Group Functions Media Relations and Public Relations at Swedbank. As previously announced, Attendo's current Director of Communications, Andreas Koch, will leave Attendo and his position in October 2024 to move on to new challenges outside the company. Announcement • Sep 13
Attendo AB (publ) to Report Q4, 2024 Results on Sep 06, 2025 Attendo AB (publ) announced that they will report Q4, 2024 results on Sep 06, 2025 Reported Earnings • Jul 22
Second quarter 2024 earnings released: EPS: kr0.28 (vs kr0.37 in 2Q 2023) Second quarter 2024 results: EPS: kr0.28 (down from kr0.37 in 2Q 2023). Revenue: kr4.84b (up 12% from 2Q 2023). Net income: kr44.0m (down 27% from 2Q 2023). Profit margin: 0.9% (down from 1.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 08
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 5.3% to €4.00. The fair value is estimated to be €3.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 53% in the next 2 years. Buy Or Sell Opportunity • Jul 05
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 5.9% to €3.97. The fair value is estimated to be €3.27, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 53% in the next 2 years. Announcement • May 15
Andreas Koch, Director of Communications, to Leave Attendo AB and His Position in the Executive Management Group Attendo AB (publ)'s Director of Communications and IR, Andreas Koch has announced that he is leaving Attendo to take up a position outside the company after almost eight years with the Group. The recruitment process to find a successor will start immediately. Andreas has been part of Attendo's Executive Management since 2016 and has developed both internal and external communication in Attendo with excellent results. Andreas will leave Attendo at latest by November 2024. He will remain in his role during the transition period. Buy Or Sell Opportunity • May 13
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 9.1% to €3.82. The fair value is estimated to be €3.13, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: kr0.39 (vs kr0.17 in 1Q 2023) First quarter 2024 results: EPS: kr0.39 (up from kr0.17 in 1Q 2023). Revenue: kr4.39b (up 8.6% from 1Q 2023). Net income: kr63.0m (up 125% from 1Q 2023). Profit margin: 1.4% (up from 0.7% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Upcoming Dividend • Apr 18
Upcoming dividend of kr1.00 per share Eligible shareholders must have bought the stock before 25 April 2024. Payment date: 02 May 2024. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (3.2%). Buy Or Sell Opportunity • Apr 10
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to €3.82. The fair value is estimated to be €3.17, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Reported Earnings • Mar 21
Full year 2023 earnings released: EPS: kr2.34 (vs kr0.28 loss in FY 2022) Full year 2023 results: EPS: kr2.34 (up from kr0.28 loss in FY 2022). Revenue: kr17.3b (up 19% from FY 2022). Net income: kr376.0m (up kr421.0m from FY 2022). Profit margin: 2.2% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Feb 27
Attendo AB (publ), Annual General Meeting, Apr 24, 2024 Attendo AB (publ), Annual General Meeting, Apr 24, 2024. Reported Earnings • Feb 09
Full year 2023 earnings released: EPS: kr2.34 (vs kr0.28 loss in FY 2022) Full year 2023 results: EPS: kr2.34 (up from kr0.28 loss in FY 2022). Revenue: kr17.3b (up 20% from FY 2022). Net income: kr376.0m (up kr421.0m from FY 2022). Profit margin: 2.2% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Jan 27
Attendo AB (publ) to Report Q4, 2023 Results on Feb 08, 2024 Attendo AB (publ) announced that they will report Q4, 2023 results at 8:00 AM, Central European Standard Time on Feb 08, 2024 Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €2.81, the stock trades at a trailing P/E ratio of 20.8x. Average forward P/E is 15x in the Healthcare industry in Germany. Total loss to shareholders of 26% over the past three years. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: kr1.43 (vs kr0.59 in 3Q 2022) Third quarter 2023 results: EPS: kr1.43 (up from kr0.59 in 3Q 2022). Revenue: kr4.49b (up 22% from 3Q 2022). Net income: kr230.0m (up 142% from 3Q 2022). Profit margin: 5.1% (up from 2.6% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Sep 28
Attendo AB (Publ) Appoints Patrik Högberg as Business Area Director for Attendo Scandinavia Attendo has appointed Patrik Högberg as new Business Area Director for Attendo Scandinavia and member of Attendos´s Executive Management Group. Most recently, Patrik was Managing Director of the company Loomis' UK operations and he has previously held several leading positions in the private and public sector. Patrik Högberg, born in 1968, has an educational background in economics and marketing, including an MBA from Stockholm University. He comes most recently from Loomis, where he held several different positions, most recently as Managing Director in the UK. Before that, he was, among other things, CEO of Norstedts Juridik and CEO of Svensk Kassaservice. Patrik will take up the position at the beginning of November 2023. At the same time, he will also become part of Attendo's Group Executive Management. Reported Earnings • Jul 20
Second quarter 2023 earnings released: EPS: kr0.37 (vs kr0.39 loss in 2Q 2022) Second quarter 2023 results: EPS: kr0.37 (up from kr0.39 loss in 2Q 2022). Revenue: kr4.33b (up 22% from 2Q 2022). Net income: kr60.0m (up kr123.0m from 2Q 2022). Profit margin: 1.4% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. New Risk • Jul 04
New major risk - Revenue and earnings growth Earnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.1% net profit margin). Board Change • May 03
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Director Antti Ylikorkala was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman of the Board Ulf Mattsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 23
Full year 2022 earnings released: kr0.28 loss per share (vs kr0.35 profit in FY 2021) Full year 2022 results: kr0.28 loss per share (down from kr0.35 profit in FY 2021). Revenue: kr14.5b (up 13% from FY 2021). Net loss: kr45.0m (down 180% from profit in FY 2021). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 12
Full year 2022 earnings released: kr0.28 loss per share (vs kr0.35 profit in FY 2021) Full year 2022 results: kr0.28 loss per share (down from kr0.35 profit in FY 2021). Revenue: kr14.5b (up 13% from FY 2021). Net loss: kr45.0m (down 180% from profit in FY 2021). Revenue is forecast to grow 6.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Jan 11
Attendo AB (publ) Announces Fredrik Lagercrantz to Resign as Chief Financial Officer, at the End of the First Half of 2023 Attendo AB (publ)'s Chief Financial Officer (CFO) Fredrik Lagercrantz, has announced that he is leaving for a position outside the company after more than five years in the Group. The recruitment process to find a successor will begin immediately. Fredrik Lagercrantz will leave Attendo at the end of the first half of 2023. He will remain in his role during the transition period. Announcement • Dec 02
Attendo AB (Publ) Announces Changes to Nomination Committee Attendo AB (publ)'s nomination committee is appointed at the Annual General Meeting. The composition may change if there are changes in ownership after the meeting. Marianne Nilsson, representing Swedbank Robur, has left Attendo's nomination committee due to changes in ownership. Attendo's nomination committee for the 2023 Annual General Meeting therefore consists of: chairman Peter Hofvenstam (Nordstjernan), Anssi Soila (appointed by Pertti Karjalainen) and Niklas Antman (Incentive AS). Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman of the Board Ulf Mattsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: kr0.59 (vs kr0.58 in 3Q 2021) Third quarter 2022 results: EPS: kr0.59 (up from kr0.58 in 3Q 2021). Revenue: kr3.71b (up 14% from 3Q 2021). Net income: kr95.0m (up 1.1% from 3Q 2021). Profit margin: 2.6% (down from 2.9% in 3Q 2021). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Oct 07
Attendo AB (publ) to Report Fiscal Year 2022 Results on Feb 10, 2023 Attendo AB (publ) announced that they will report fiscal year 2022 results on Feb 10, 2023 Announcement • Sep 14
Attendo AB (publ) Appoints Jo-Anna Nordström as Member of the Executive Management Team Attendo AB (publ) announced that its general counsel Jo-Anna Nordström becomes a member of the Executive management team and, at the same time, resumes the responsibility for Attendo's overall sustainability work. Over the past year, Attendo has developed the sustainability strategy, and with Jo -Anna in charge, this focus is being strengthened. Eric Wåhlgren, Attendo's Business Development Director, is also given increased responsibility for the quality development work at group level. Jo-Anna Norström has a Master of Laws from Uppsala University and earlier in her career worked as a lawyer at Linklaters and Vinge, among others. Jo-Anna has been employed at Attendo as general counsel since 2019 and will, become a member of the executive management team and will be responsible for the company's overall sustainability work in addition to her current role. Reported Earnings • Jul 22
Second quarter 2022 earnings released: kr0.39 loss per share (vs kr0.12 loss in 2Q 2021) Second quarter 2022 results: kr0.39 loss per share (down from kr0.12 loss in 2Q 2021). Revenue: kr3.55b (up 11% from 2Q 2021). Net loss: kr63.0m (loss widened 232% from 2Q 2021). Over the next year, revenue is forecast to grow 6.5%, compared to a 4.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • May 07
First quarter 2022 earnings released: kr0.20 loss per share (vs kr0.062 loss in 1Q 2021) First quarter 2022 results: kr0.20 loss per share (down from kr0.062 loss in 1Q 2021). Revenue: kr3.49b (up 14% from 1Q 2021). Net loss: kr33.0m (loss widened 230% from 1Q 2021). Over the next year, revenue is forecast to grow 6.2%, compared to a 4.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year whereas the company’s share price has fallen by 21% per year. Board Change • May 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman of the Board Ulf Mattsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 27
Attendo AB (Publ) Announces Board and Committee Changes Attendo AB (publ) at the Annual General Meeting resolved that the number of Board members shall be seven,Ulf Mattsson was elected as new Board member and Chair of the Board of Directors. The Annual General Meeting resolved to elect the following Nomination Committee: Peter Hofvenstam (nominated by Nordstjernan), Niklas Antman (nominated by Incentive AS) and Marianne Nilsson (nominated by Swedbank Robur Fonder), with Peter Hofvenstam as Chair of the Nomination Committee. Reported Earnings • Feb 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr0.35 (up from kr5.63 loss in FY 2020). Revenue: kr12.9b (up 4.9% from FY 2020). Net income: kr56.0m (up kr962.0m from FY 2020). Profit margin: 0.4% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 7.6%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS kr0.58 (vs kr0.40 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr3.26b (up 9.3% from 3Q 2020). Net income: kr94.0m (up 47% from 3Q 2020). Profit margin: 2.9% (up from 2.1% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 23
Second quarter 2021 earnings released: kr0.12 loss per share (vs kr6.07 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: kr3.22b (up 3.3% from 2Q 2020). Net loss: kr19.0m (loss narrowed 98% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Reported Earnings • May 07
First quarter 2021 earnings released: kr0.062 loss per share (vs kr0.019 profit in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: kr3.07b (down 1.9% from 1Q 2020). Net loss: kr10.0m (down 433% from profit in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 18
Full year 2020 earnings released: kr5.63 loss per share (vs kr0.50 profit in FY 2019) The company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr12.3b (up 3.0% from FY 2019). Net loss: kr906.0m (down kr987.0m from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Announcement • Mar 11
Attendo AB (publ), Annual General Meeting, Apr 14, 2021 Attendo AB (publ), Annual General Meeting, Apr 14, 2021. Agenda: To consider election of the chair of the annual general meeting; to consider election of one or two persons to verify the minutes; to consider approval of the voting register; to consider approval of the agenda; to consider presentation of the parent company's annual report and auditor's report, as well as the consolidated financial statements and the auditor's report for the attendo group; to consider resolutions to adopt the parent company's income statement and balance sheet, as well as the consolidated income statement and the consolidated balance sheet for the attendo group; to consider resolution on allocation of the company's result in accordance with the approved balance sheet; and to consider other matters. Announcement • Mar 04
Attendo AB (publ) (OM:ATT) agreed to acquire Uudenmaan Seniorikodit Oy from Aava Terveyspalvelut Oy. Attendo AB (publ) (OM:ATT) agreed to acquire Uudenmaan Seniorikodit Oy from Aava Terveyspalvelut Oy on March 2, 2021. Uudenmaan Seniorikodit Oy reported turnover of €20 million. Analyst Estimate Surprise Post Earnings • Feb 11
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 4.3%, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Is New 90 Day High Low • Feb 03
New 90-day high: €4.61 The company is up 15% from its price of €4.00 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.45 per share. Is New 90 Day High Low • Jan 15
New 90-day high: €4.59 The company is up 3.0% from its price of €4.45 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.77 per share. Is New 90 Day High Low • Oct 26
New 90-day low: €4.12 The company is down 6.0% from its price of €4.36 on 28 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.77 per share. Reported Earnings • Oct 25
Third quarter earnings released Over the last 12 months the company has reported total losses of kr949.0m, with earnings decreasing by kr1.07b from the prior year. Total revenue was kr12.3b over the last 12 months, up 4.9% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 25
Third-quarter earnings released: Revenue misses expectations Third-quarter revenue missed analyst estimates by 4.8% at kr2.98b. Revenue is forecast to grow 7.2% over the next year, compared to a 4.1% growth forecast for the Healthcare industry in Germany. 
